New Launch12 Aug 2026, 05:16 pm
Speciality Medicines Gets Ethiopia Approval for 2 New Products
AI Summary
Speciality Medicines Limited has secured regulatory approval from Ethiopia's health authority for two new speciality pharmaceutical formulations: Olanzapine Tablets 5 mg (Olazyn 5) and Diazepam Tablets 5 mg (Diazem 5). This expands the company's registered product portfolio in Ethiopia to 12 formulations, further strengthening its export footprint in the African region. The approvals are valid for 5 years and add to the company's CNS therapeutic portfolio. This move is part of Speciality Medicines' broader export expansion strategy, with additional filings under review in multiple overseas markets. The company aims to deepen its international presence and support long-term export growth.
Key Highlights
- Ethiopia grants regulatory approval for two new speciality pharmaceutical products.
- Expands company's Ethiopian portfolio to 12 formulations.
- Strengthens presence in African markets and CNS therapeutic portfolio.
- Part of a broader international expansion strategy with ongoing filings.
Price Impact
More from SPML